PRINCETON, N.J. — Dr. Reddy’s Laboratories recently introduced its generic of Vidaza (azacitidine for injection, 100 mg/vial) in Canada. The drug is indicated to treat patients with various subtyped of FAB myelodysplastic syndrome.
“Bringing azacitidine for injection to the Canadian market at this time is very important for us, as well as for our customers and their patients,” Dr. Reddy’s executive vice president and head of North America generics Alok Sonig said. “This launch represents Dr. Reddy’s commitment to make affordable injectable drugs available in Canada.”
Dr. Reddy’s said it is first to market this generic in Canada.
November 10, 2017